Joydeep Goswami

CFO, Chief Strategy and Corporate Development Officer @Illumina. Working to improve human health by unlocking the power of the genome

[Joydeep Goswami @JoydeepGoswami]

Our new partnership with Pillar Biosciences allows @Illumina to offer a broader portfolio to customers and will result in better care for patients by improving access to personalized cancer treatment options.

[Kevin Keegan @keegan_ke]

Check it out, @illumina announced today to partner with @Pillar_Bio to commercialize their portfolio of targeted oncology assays to customers and clinicians around the world. https://t.co/quYxgh5KYF

[Joydeep Goswami @JoydeepGoswami]

https://t.co/2vKXB8XJWc

[Joydeep Goswami @JoydeepGoswami]

The Alliance for Genomic Discovery, launched by @Illumina and Nashville Biosciences, now includes founding members AbbVie, Amgen, AstraZeneca, Bayer, and Merck – a world-class collaboration to accelerate development of therapeutics through large-scale #genomics.

[Illumina @illumina]

Update: Today we welcome @AbbVie @Amgen @AstraZeneca @BayerPharma @Merck as founding members of the newly named Alliance for Genomic Discovery in collaboration with @NashvilleBio. Together we’ll work to accelerate therapeutic development and expand the diversity of genomic data.

[Joydeep Goswami @JoydeepGoswami]

At Illumina, we’re unlocking the power of #genomics to positively impact the world and shape a more sustainable, equitable future for all. Released on this #WorldEnvironmentDay, Illumina’s 2022 Corporate Social Responsibility report details progress against five key priorities.

[Illumina @illumina]

In celebration of #WorldEnvironmentDay, we’re excited to share our new 2022 CSR impact report, highlighting achievements like 100% of our electricity consumption coming from renewable sources. See more of our progress in our 2022 CSR Report here: https://t.co/tqCVu4AUMY

[Joydeep Goswami @JoydeepGoswami]

Exciting news of PrimateAI-3D, an #AI algorithm predicting disease-causing genetic mutations in patients. Study results are published in the June 2 issue of Science Magazine. Genomic data is revolutionizing R&D productivity, reducing timelines to new drugs and late stage failures

[Illumina @illumina]

Discover results published in the latest issue of Science Magazine, using our new PrimateAI-3D, an #AI algorithm, that predicts disease-causing genetic mutations with unprecedented accuracy.

[Joydeep Goswami @JoydeepGoswami]

Honored to serve our global customers, whose demand lifted NovaSeq X orders in Q1 to 200+! We can’t wait to see what breakthroughs our customers will make with it. https://t.co/gKfISziSal #illumina

[Joydeep Goswami @JoydeepGoswami]

#IlluminaProud of our colleagues, customers, and partners who rang the closing bell yesterday at #Nasdaq in honor of Illumina’s 25th anniversary!

[Illumina @illumina]

We rang the @nasdaq Bell in celebration of Illumina’s 25th anniversary! 🔔 It’s inspiring how far we’ve come and all we’ve accomplished – knowing we wouldn’t be here without our innovative employees, customers & partners. Here’s to the next 25! #Nasdaq #IlluminaProud

[Joydeep Goswami @JoydeepGoswami]

Our expanded partnership with @myriadgenetics holds the potential to expand access to pan-cancer HRD testing, enabling insights into new treatments for ovarian, breast, prostate, and pancreatic cancers. #genomics4all

[Kevin Keegan @keegan_ke]

Thrilled to announce the expansion of @illumina strategic partnership with @myriadgenetics to broaden access and availability of oncology HRD testing in the US. https://t.co/OyjduBequQ

[Joydeep Goswami @JoydeepGoswami]

Deeply honored and excited to continue working with Illumina’s world-class Finance team in support of our mission.

[Illumina @illumina]

With more than 20 years of industry experience and various senior and international leadership roles, we are pleased to announce that Joydeep Goswami has been named our Chief Financial Officer, effective immediately. https://t.co/MEGi53XTRv

[Joydeep Goswami @JoydeepGoswami]

The agreement between @Illumina @NashvilleBio and @Amgen @decodegenetics to sequence 35,000 DNA samples from African American patients @VanderbiltHealth will help diversify genomic research and deliver on the promise of #precisionmedicine for all. Learn more.

[Joydeep Goswami @JoydeepGoswami]

I’m proud of the work we’re doing @illumina under Francis’ leadership to make access to genomics more accessible, affordable, and sustainable. Kudos on the well-deserved recognition, @fdesouza

[Illumina @illumina]

Congratulations to our CEO, @fdesouza, for being awarded one of @3BLMedia's Responsible CEO of the Year.

Francis is dedicated to empowering Illumina to help shape a more equitable and #sustainable future. https://t.co/8ckp5KYHzr

[Joydeep Goswami @JoydeepGoswami]

Congratulations to everyone involved in securing this strategic research partnership with @AstraZeneca. By combining the power of our AI tools, we can help accelerate the development of safe and effective therapies. #Genomics4Good

[Illumina @illumina]

We are proud to partner with @AstraZeneca, one of the world’s leading pharmaceutical companies, to accelerate drug discovery using AI. Together, our AI tools can help accelerate the development of safe and effective #therapies. Learn more: https://t.co/5Kj1Ie9Ydf

[Joydeep Goswami @JoydeepGoswami]

Thank you to @JournPrecMed for the invitation to share my thoughts about the future of #precisionmedicine with my esteemed colleague @PhilFebboMD_CMO. We’ll share much more later this week as Illumina unveils its Innovation Roadmap at #IGF

[Phillip Febbo, MD @PhilFebboMD_CMO]

https://t.co/rjnZgthvv6

[Joydeep Goswami @JoydeepGoswami]

Really looking forward to hearing @ChrissieEvert talk about her life and the role #genomics played in her recent #ovariancancer diagnosis and treatment. Join us next month by registering for #IGF at https://t.co/HKOu2yU2Rd

[Illumina @illumina]

She’s a tennis legend. She beat cancer. And now she’s a guest speaker at #IGF. Don’t miss @ChrissieEvert joining us for a powerful fireside chat, “Taking on My Nastiest Opponent Yet." https://t.co/H1OAm9YGpk

[Joydeep Goswami @JoydeepGoswami]

Looking forward to hearing @AbasiEneobong talk about his work to provide greater access to and equity within #genomic #sequencing. #IGF

[Joydeep Goswami @JoydeepGoswami]

What a great way to start the week! Proud of the culture of support and care @Illumina.

[Francis deSouza @fdesouza]

We’re honored to be selected as #15 on @JustCapital’s Top 100 US Companies Supporting Healthy Families & Communities. The goal of @illumina’s culture of care is to support families and communities through these challenging times, and always. https://t.co/MYNUr0zoCe

[Joydeep Goswami @JoydeepGoswami]

Nice to see @American_Heart support the use of polygenic risk score (PRS) analysis in the prevention of #heartdisease. Research by @Illumina and @Allelica_PRS shows that using PRS to guide preventive statin therapy can save lives and reduce U.S. #healthcare spending.

[Circulation @CircAHA]

Polygenic Risk Scores for Cardiovascular Disease #AHAJournalshttps://www.ahajournals.org/doi/10.1161/CIR.0000000000001077

[Joydeep Goswami @JoydeepGoswami]

Really excited and honored have President Obama participate in the Illumina Genomics Forum!

[Illumina @illumina]

SPECIAL ANNOUNCEMENT: Former US President Barack Obama will participate in a moderated conversation on September 28 at the Illumina Genomics Forum. Join us for an important conversation. Register now: https://t.co/VEDzVYXeNH

[Joydeep Goswami @JoydeepGoswami]

Adding the HRD signature to TSO 500 allows researchers to learn more about the genomic profile of cancers such as breast, ovary, pancreas and prostate, with the hope of unlocking new therapies for patients.

[Illumina @illumina]

Partnering w/ @Merck we launched RUO TruSight™ Oncology 500 HRD, a research test to identify genetic mutations in the assessment of homologous recombination deficiency (HRD). This will enable labs deeper insights into the genomic nature of cancer tumors. https://t.co/2FeVXbevjQ

[Joydeep Goswami @JoydeepGoswami]

Don’t miss my colleagues and a panel of leading oncologists as they discuss the transformational impact of CGP at this week’s @ASCO meeting. Through the power of #precisionmedicine, we can revolutionize and personalize the diagnosis and treatment of cancer.

[Illumina @illumina]

"At Illumina, we are seeing increased adoption of comprehensive genomic profiling (CGP) in both in-house pathology labs and centralized labs to inform and enhance patient care" @keegan_ke VP and GM, Oncology live from #ASCO22 https://t.co/6XcBL6TT8D